Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

British Journal of Cancer

Volumn 79, Issue 7-8, 1999, Pages 1220-1226

  Houston, S J ^a   Plunkett, T A ^a   Barnes, D M ^a   Smith, P ^a   Rubens, R D ^a   Miles, D W ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; c erbB2; Endocrine therapy; Tamoxifen

Indexed keywords

ANTIESTROGEN; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE NEU; PRIORITY JOURNAL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 0032982818     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690196     Document Type: Article

References (45)

1. Allred DC, Clark G, Tandon A, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC and McGuire WL (1992) HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10: 599-605
2. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hinna W, Lickley L, Wilkinson R, Qizlbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W and McCready D (1998) neu/erbB2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 16: 1340-1349
3. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI and Robertson JF (1995) Expression of ras p21, p53 and c-erbB2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72: 1259-1266
4. Barnes DM, Lammie GA, Millis RR, Gullick WJ, Allen DS and Altman DG (1988) An immunohistochemical evaluation of c-erbB2 expression in human breast carcinoma. Br J Cancer 58: 448-452
5. Barnes DM, Millis RR, Beex LVAM, Thorpe SM and Leake RE (1998) Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. Eur J Cancer 34: 1677-1682
6. Baselga J, Tripathy D, Mendelsohn J, Baugham S, Benz CC, Dantis L, Sklarin NJ, Seidman AD, Hndis CA, Moore J, Rosen PP, Twaddell T, Henderson IC and Norton L (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737-744
7. Benz CC, Scott GK and Sarup JC (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24: 85-95
8. Berns EMJJ, Foekens JA, van Staveren IL, van Putten WLJ, de Koning HYWCM, Portengen H and Klijn JGM (1995) Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159: 11-18
9. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S and Sigurdsson H (1994) ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81: 137-144
10. Carlomagno C, Perrone F, Gallo C, De Laurentis MD, Lauria R, Morabito A, Pettinato G, Panico L D'Antonio A, Bianco R and De Placido S (1996) c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14: 2702-2708
11. Charpin C, Garcia S, Bouvier C, Martini F, Lavaut M-N, Allasia C, Bonnier P and Andrac L (1997) c-erbB2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival. Br J Cancer 75: 1667-1673
12. Ciocea DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen GJ, Pounds GW, Vendely P, Owens MA, Pandian MR and McGuire WL (1992) Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 84: 1279-1282
13. Clinical Practice Guidelines for the Use of Tumor Markers in Breast and Colorectal Cancer (1996). J Clin Oncol 14: 2843-2877
14. Coussens L, Yang-Feng TL, Liao TL, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A and Ullrich A (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139
15. Elledge RM, Green S, Ciocca D, Pugh R, Allred CA, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S and Osborne CK (1998) HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group study. Clin Cancer Res 4: 7-12
16. Elston CW (1984) The assessment of histological differentiation in breast cancer. Aust NZ J Surg 54: 11-15
17. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL and Altman DG (1991) c-erbB2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434-438
18. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam C-M, Goloum R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Burki K, Castiglione M, Collins J, Lintner J and Senn H-J (1992) Prognostic importance of c-erbB2 expression in breast cancer. J Clin Oncol 10: 1049-1056
19. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A and Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289-1294
20. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE and Yarden Y (1996) ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15: 254-264
21. Kath R, Hoffken K and Otte C (1993) The neu oncogene product in serum and tissue of patients with breast carcinoma. Ann Oncol 4: 585-590
22. Kern FG, Cheville AL and Liu Y (1990) Growth factor receptors and the progression of breast cancer. Semin Cancer Biol 1: 317-328
23. King RJB, Redgraves J and Hayward JL (1979) The measurement of receptors for oestradiol and proesterone in human breast tumours. In Steroid Receptor Assays in Breast Tumours: Methodological and Clinical Aspects, King RJB (ed), p. 55-73. Alpha-Omega: Cardiff
24. Klijn JGM, Berns EMJJ, Bontebal M and Foekens J (1993) Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat Rev 19SB: 45-63
25. Kuukasjarvi T, Kononen J, Helin H, Holli K and Isola J (1996) Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14: 2584-2589
26. Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L, Podczaski E, Harvey H, Shambaugh S, Volas G, Weaver S and Lipton A (1992) Elevated soluble c-erbB2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 10: 1436-1443
27. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L and Lipton A (1995) Elevated serum c-erbB2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 1129-1135
28. Manni T, Trujillo JE and Marshall (1989) Anti-hormone treatment of stage IV breast cancer. Cancer 43: 444-150
29. Newby JC, Johnston SRD, Smith IE and Dowsett M (1997) Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3: 1643-1651
30. Niehans GA, Singleton TP and Dykoski D (1993) Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 5: 1230-1235
31. O'Malley FP, Saad Z, Kerkvliet N, Doig G, Stitt L, Ainsworth P, Hundal H, Chambers AF, Turnbull DI and Bramwell V (1996) The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erbB2 in lymph node negative breast cancer. Hum Pathol 27: 955-963
32. Pietras RJ, Arboleda J and Reese DM (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435-2446
33. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Brandeis J, Paterson MC and Slamon DJ (1993) Her-2/neu expression in node-negative breast cancer: direct tissue quantitution by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53: 4960-4970
34. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou J-Y, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Philips RN, Ross JS, Wolman SR and Flom KJ (1997) HER-2/neu gene amplification characterised by fluoresence in situ hybridisation: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894-2904
35. Ravdin PM, Green S, Door TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, Metch B and Osborne CK (1992) Prognostic significance of progesterone receptor levels in estrogen rcceptor-postive patients with metastatic breast cancer treated with tamoxifen: results of a prospective SWOG study. J Clin Oncol 10: 1284-1291
36. Rubens RD and Hayward JL (1980) Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer. Cancer 46: 2922-2924
37. Saceda M. Grunt TW, Colomer R, Lippman ME, Lupu R and Martin MB (1996) Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines. Endocrinology 137: 4322-4330
38. Sjogren S, Inganas M, Lindgren A, Holmberg L and Bergh J (1998) Prognostic and predictive value of c-erbB2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16: 462-469
39. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ulrich A and McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182
40. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF (1989) Studies of the HER-2/neu proto-oncogene in human breast cancer and ovarian cancer. Science 244: 707-712
41. Stal O, Ferno M, Borg A and Nordenskjold B (1997) ERBB2 expression and benefit from 5 versus 2 years of adjuvant tamoxifen for postmenopausal stage II breast cancer patients. Breast Cancer Res Treat 46: 32 (abstr)
42. Tetu B and Brisson J (1994) Prognostic significance of the pattern of immunostaining and adjuvant therapy. Cancer 73: 2358-2365
43. Witters LM, Kumar R, Chinchilli VM and Lipton A (1997) Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 42: 1-5
44. Wright C, Nicholson S, Angus B, Sainsbury JRC, Farndon J, Cairns J, Harris AL and Horne C (1992) Relationship between c-erbB2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65: 118-121
45. Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hosch S and Hayes DF (1997) Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15: 2518-2525